| Description | RO6889678 is HBV inhibitor with a complex ADME profile. |
| In vitro | RO6889678, a novel inhibitor of HBV with a complex absorption, distribution, metabolism, and excretion (ADME) profile.?RO6889678 showed an intracellular enrichment of 78-fold in hepatocytes, with an apparent intrinsic clearance of 5.2 l/min per mg protein and uptake and biliary clearances of 2.6 and 1.6 l/min per mg protein, respectively.?When apparent intrinsic clearance was incorporated into a PBPK model, the simulated oral human profiles were in good agreement with observed data at low doses but were underestimated at high doses due to unexpected overproportional increases in exposure with dose.?In addition, the induction potential of RO6889678 on cytochrome P450 (P450) enzymes and transporters at steady state was assessed and cotreatment with ritonavir revealed a complex drug-drug interaction with concurrent P450 inhibition and moderate UDP-glucuronosyltransferase induction. |
| molecular weight | 494.92 |
| Molecular formula | C21H20ClFN4O5S |
| CAS | 1578153-27-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (111.13 mM) |
| References | 1. Kratochwil N A , Triyatni M , Mueller M B , et al. Simultaneous Assessment of Clearance, Metabolism, Induction and Drug-Drug Interaction Potential using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor[J]. Journal of Pharmacology & Experimental Therapeutics, 2018:jpet.117.245712. |